Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLO1 | Q04760 | 10/20 | 0.55 |
| ▸ | CA1 | P00915 | 5/20 | 0.43 |
| ▸ | CA2 | P00918 | 5/20 | 0.43 |
| ▸ | CA12 | O43570 | 4/20 | 0.43 |
| ▸ | CA9 | Q16790 | 4/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | BRD2 | P25440 | 1/20 | 0.43 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25759561 | 0.81 | GLO1 (0.38) | GLO1ALDH1A1 | |
| SCHEMBL8819088 | 0.78 | CA2 (0.47) | GLO1CA1CA2CA12CA9 | |
| SCHEMBL12619213 | 0.77 | CA2 (0.36) | GLO1CA1CA2CA12CA9 | |
| SCHEMBL12671231 | 0.77 | CA1 (0.46) | CA1CA2CA12CA9MAOB | |
| SCHEMBL12173001 | 0.77 | PKM (0.55) | CA1CA2CA12CA9BRD4 | |
| SCHEMBL1299062 | 0.75 | ALDH1A1 (0.56) | GLO1CA1CA2CA12CA9 | |
| SCHEMBL19625168 | 0.75 | GLO1 (0.39) | GLO1CA1CA2CA12CA9 | |
| SCHEMBL1925948 | 0.74 | CA2 (0.52) | CA1CA2CA12CA9BRD4 | |
| SCHEMBL31452114 | 0.74 | L3MBTL1 (0.53) | GLO1CA1CA2CA12CA9 | |
| SCHEMBL342932 | 0.74 | L3MBTL1 (0.53) | GLO1CA1CA2CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122846-A1 | FURO[3,2-d]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122846-A1 | FURO[3,2-d]PYRIMIDINE COMPOUNDS | CDK2, DPYD, CDK3 | GLO1 3155/4885CA1 4308/4885CA2 3413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.